Abstract
Methicillin-resistant Staphylococcus aureus, first identified just over 4 decades ago, has undergone rapid evolutionary changes and epidemiologic expansion. It has spread beyond the confines of health care facilities, emerging anew in the community, where it is rapidly becoming a dominant pathogen. This has led to an important change in the choice of antibiotics in the management of community-acquired infections and has also led to the development of novel antimicrobials.
MeSH terms
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use
-
Bacterial Proteins / genetics
-
Community-Acquired Infections* / drug therapy
-
Community-Acquired Infections* / epidemiology
-
Community-Acquired Infections* / microbiology
-
Evolution, Molecular*
-
Humans
-
Methicillin Resistance* / genetics
-
Molecular Epidemiology
-
Staphylococcal Infections* / drug therapy
-
Staphylococcal Infections* / epidemiology
-
Staphylococcal Infections* / microbiology
-
Staphylococcus aureus* / classification
-
Staphylococcus aureus* / drug effects
-
Staphylococcus aureus* / genetics
-
Staphylococcus aureus* / pathogenicity
Substances
-
Anti-Bacterial Agents
-
Bacterial Proteins